

1 **Spectrum of neurological manifestations and systematic evaluation of cerebrospinal fluid for**
2 **SARS-CoV2 in patients admitted to hospital during the COVID-19 epidemic in South Africa**

3

4 Angharad G Davis^{1,2,3}

5 Marise Bremer¹

6 Georgia Schäfer^{1, 4}

7 Luke Dixon⁵

8 Fatima Abrahams¹

9 Rene T Goliath¹

10 Mpumi Maxebengula¹

11 Alize Proust²

12 Anesh Chavda⁷

13 John Black⁸

14 Robert J Wilkinson^{1,2,3,6}

15 And the HIATUS Study Consortium

16

17 **Affiliations**

18 1. Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Observatory
19 7925, Republic of South Africa

20 2. The Francis Crick Institute, Midland Road, London, NW1 1AT, United Kingdom

21 3. Faculty of Life Sciences, University College London, WC1E 6BT, United Kingdom

22 4. International Centre for Genetic Engineering and Biotechnology (ICGEB), Observatory, Cape Town,
23 7925, Republic of South Africa

24 5. Imperial College NHS Healthcare Trust, Charing Cross Hospital, London, W6 8RF, United Kingdom

25 6. Department of Infectious Diseases, Imperial College London, London, W12 0NN, United Kingdom

26 7. Department of Radiology, West Middlesex University Hospital and Chelsea and Westminster Hospital,
27 London, United Kingdom

28 8. Department of Medicine, Walter Sisulu University, Mthatha 5117, Republic of South Africa

29 **Funding**

30 AGD is supported through a UCL Wellcome Trust PhD Programme for Clinicians Fellowship (award
31 number 175479). GS received funding through the EDCTP2 (TMA2018SF-2446 - KSHV/HIV morbidity).

32 RJW receives support from Francis Crick Institute which is funded by UKRI (FC0010218); Wellcome
33 (FC0010218) and CRUK (FC0010218). He is additionally supported EDCTP (RIA2017T-2019 109237).

34

35 This research was funded in whole, or in part, by the Wellcome Trust [Grant numbers 203135/Z/16/Z,
36 104803; 203135; 222574]. For the purpose of open access, the author has applied a CC BY public
37 copyright licence to any Author Accepted Manuscript version arising from this submission

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 **Abstract**

58

59 Neurological manifestations of COVID-19 are increasingly described in the literature. There is uncertainty

60 whether these occur due to direct neuroinvasion of the virus, para-infectious immunopathology, as result

61 of systemic complications of disease such as hypercoagulability or due to a combination of these

62 mechanisms. Here we describe clinical and radiological manifestations in a sequential cohort of patients

63 presenting to a district hospital in South Africa with neurological symptoms with and without confirmed

64 COVID-19 during the first peak of the epidemic. In these patients, where symptoms suggestive of

65 meningitis and encephalitis were most common, thorough assessment of presence in CSF via PCR for

66 SARS-CoV2 did not explain neurological presentations, notwithstanding very high rates of COVID-19

67 admissions. Although an understanding of potential neurotropic mechanisms remains an important area

68 of research, these results provide rationale for greater focus towards the understanding of para-immune

69 pathogenic processes and the contribution of systemic coagulopathy and their interaction with pre-

70 existing risk factors in order to better manage neurological disease in the context of COVID-19. These

71 results also inform the clinician that consideration of an alternative diagnosis and treatment for

72 neurological presentations in this context is crucial, even in the patient with a confirmed diagnosis COVID-

73 19.

74

75

76

77

78

79

80

81

82

83

84

85 Introduction

86

87 Although COVID-19, the disease caused by SARS-CoV2, is primarily a disease of the respiratory tract,
88 coronaviruses (CoV) are known to be neurotropic with some strains leading to meningitis, encephalitis
89 and cerebral vasculitis [20]. In the first case series of SARS-CoV2 conducted in Wuhan, China, it was
90 found that in 62 patients, 21 (34%) reported headache [1]. In a subsequent retrospective case series to
91 investigate neurological presentations in 214 patients with COVID-19, 36% of patients were found to have
92 neurological signs and symptoms, which were more frequent in severe compared to non-severe COVID-
93 19 (45% vs 30.2%). Since then, a wealth of literature suggests that SARS-CoV2 has the potential to
94 present with neurological manifestations, with or without pulmonary involvement. Reports include cases of
95 meningitis/encephalitis, with [2, 3] and without [4] detection of SARS-CoV2 within the cerebrospinal fluid
96 (CSF), stroke [5], transverse myelitis [6-8], acute disseminated encephalomyelitis [9] and inflammatory
97 polyradiculopathies such as Guillain-Barre Syndrome [10-13]. Whether the mechanism by which these
98 phenomena occur are due to, either individually or in combination, direct neurotropic invasion, para- or
99 post-infectious inflammation, a systemic coagulopathic processes or indeed due to separate and co-
100 incidental pathogenic processes is not well understood.

101

102 The distinction between direct CNS invasion and other potential mechanisms is however important to
103 make. Clinicians who assess patients presenting with neurological symptoms in the context of a COVID-
104 19 epidemic must know when and how to investigate for neurological complications of SARS-CoV2
105 infection. Moreover, should SARS-CoV2 commonly lead to neurological symptoms via direct CNS
106 invasion, particularly in the absence of pulmonary symptoms, then patients should be screened routinely
107 for neurological involvement, and physicians must consider this unique potential of the virus. If direct
108 SARS-CoV2 invasion to the CNS does not explain neurological presentations in this context, then greater
109 focus must be towards understanding the nature and contribution of para- and post-infectious
110 inflammatory phenomenon and coagulopathy in order to develop effective therapeutics to treat these
111 often severe complications of disease. This is particularly important in resource limited settings where
112 testing for SARS-CoV2 is not always available, and as yet there are no bespoke methods to test for

113 SARS-CoV2 in cerebrospinal fluid (CSF). In these settings the precise incidence of SARS-CoV2 infection
114 may not be known, or be underestimated: in the Eastern Cape of South Africa for instance where this
115 study took place, seroprevalence following the first wave of the epidemic has been found to be as high as
116 62.5% in adults under the age of 65 years which is 8-fold higher than the official case count [14], and has
117 led to death in an estimated 1 in 300 people in the region (SAMRC data) [15]. Such high rates of infection
118 and subsequent mortality not only calls for better resource to manage the disease in these settings, but
119 should also alert the clinician to the increased possibility of encountering less typical presentations of
120 SARS-CoV2 infection.

121
122 To date no published studies have systematically investigated for the presence of SARS-CoV2 within the
123 CNS in patients presenting with neurological symptoms with and without pulmonary manifestations of
124 COVID-19 in a context where COVID-19 infection is the most frequent reason for hospital admission. In a
125 prospective cohort study in the Eastern Cape of South Africa, we described clinical and radiological
126 features, and assessed for the presence of SARS-CoV2 within the CNS in those presenting to hospital
127 with neurological symptoms during the first peak of the COVID-19 epidemic.

128

129 **Methods**

130 *Patient recruitment*

131 We undertook a prospective cohort study at Livingstone Hospital, Eastern Cape. The study was approved
132 by the Faculty of Health Sciences Human Research Ethical Committee of the University of Cape Town
133 (HREC 207/2020) and by the ethical review board at Livingstone Hospital. We sequentially enrolled adults
134 (>18 years) presenting with neurological symptoms who at the discretion of the treating physician
135 required inpatient investigation by lumbar puncture and cerebrospinal analysis between 12th July and 20th
136 October 2020. During this time Livingstone Hospital served as a COVID-19 referral centre in the Eastern
137 Cape with an average admission rate of 40 confirmed COVID-19 cases per day. Written informed consent
138 was taken from the patients where possible in those with capacity to consent. In those with decreased
139 consciousness, patient relatives were approached for proxy consent. In those where no relative was

140 contactable, permission was sought on an individual case basis by the Faculty of Health Sciences Human
141 Research Ethical Committee of the University of Cape Town.

142
143 *Clinical and radiological data collection*
144 Clinical data was collected on symptoms and signs at presentation as well as relevant past medical
145 history at two timepoints (baseline, and again between 3 and 7 days of enrolment). Computerised
146 Tomography (CT) head images performed as part of standard of care included as routine sagittal and
147 axial views. Two dimensional images were retrieved and independently viewed using a picture archive
148 and communication system (PACS) by a blinded neuroradiologist using a standardised case report form.
149 No specific study procedures took place, however at the time of diagnostic lumbar puncture a total of 6 ml
150 of additional CSF was retrieved for study specific analysis and biobanking. Similarly, venipuncture was
151 not performed as a study procedure, however 24 ml of additional whole blood samples were collected for
152 study specific blood work up and biobanking. Data on routine blood and CSF investigations performed as
153 part of the diagnostic work up were collected from the National Health Laboratory Database and patient
154 medical record. The outcome of admission (including death and final diagnosis) were recorded
155 retrospectively.

156
157 *Laboratory methods to detect SARS-CoV2 in CSF*
158 An in-house RT-PCR that compared well with the routine nationally employed test, the Multiplex
159 TaqMan™2019-nCoV kit (Applied Biosystems, Waltham, Massachusetts, USA) was established and used
160 to detect SARS-CoV2 in CSF targeting the E gene and subgenomic RNA (sgRNA). Viral subgenomic
161 mRNA is transcribed only in infected cells and not packaged into virions and therefore a positive sample
162 may indicate evidence of actively infected cells within the CSF[16]. RNA was extracted from patient
163 samples using the E.Z.N.A. Viral RNA kit (Omega Bio-tek), followed by reverse transcription and PCR-
164 amplification of the SARS-CoV2-specific targets E and sgRNA (as well as a human RNA control, RNaseP
165 (RP)) using the TaqPath™ 1-Step Master Mix kit (Thermo Fisher) on a QuantStudio 7 Real-Time PCR
166 machine (Thermo Fisher). Primers and probes for SARS-CoV2 E gene and sgRNA readouts have been
167 published elsewhere [17] and were synthesized by Inqaba Biotec (South Africa), while primers and

168 probes for the RP control target were provided by the CDC 2019-Novel Coronavirus (2019-nCoV) Real-
169 Time RT-PCR Diagnostic Panel. Each run included a positive control (PC), which for sgRNA runs
170 included a sample from a previously positive patient, a human specimen extraction control (HSC; e.g.
171 HeLa cell RNA) as well as a no template control (NTC, i.e. water). All samples were amplified under the
172 same conditions using 400nM concentrations of each of the primers, as well as 200nM of probe. Thermal
173 cycling involved 10min at 53°C for reverse transcription, followed by 3min at 95°C to deactivate Reverse
174 Transcriptase and Taq activation, and 45 cycles of 3s at 95°C and 30s at 57°C. A run was considered
175 valid if the control samples yielded the following results with a Ct value < 40 being considered a positive
176 signal: NTC negative for E, sgRNA and RP; HSC negative for E and sgRNA, positive for RP; PC: positive
177 for E, sgRNA and RP. When all controls exhibited the expected performance, an unknown patient sample
178 was considered negative if the Ct values for E and sgRNA were > 37 AND the Ct value for RP < 37. A
179 specimen was considered positive if the Ct values for E and sgRNA were < 37. Runs with a CT between
180 37 and 40 were repeated.

181

182 *Statistical analysis*

183 Data was analysed as an entire cohort with continuous characteristics described in terms of median
184 values and interquartile ranges, and dichotomous variables as counts and percentages. Comparison
185 between patients who tested positive for SARS-CoV2 on nasopharyngeal (NP) swab PCR, and those who
186 did not was assessed using Wilcoxon rank-sum tests to compare continuous variables, and chi squared
187 test for dichotomous variables. All analysis was performed within GraphPad Prism (version 9, Prism for
188 MacOS) software.

189

190 **Results**

191 At total of 40 participants (24 female, 16 male) were screened for inclusion in the study. One participant
192 was not enrolled as neither deferred and proxy consent were available. Therefore, 39 participants were
193 included within the analysis. The median age at enrollment was 44 years. Baseline characteristics are
194 outlined in table 1. At the time, routine testing for SARS-CoV2 by NP swab was not available for all
195 inpatients due to limited resource; however, 31/39 participants included within this study underwent

196 testing due to symptomatic presentation, or recent COVID-19 contact. 7/31 participants tested positive for
197 SARS-CoV2 via NP swab. In tables 1 and 2, demographics and clinical characteristics of the cohort are
198 described, as well as for those who tested positive and negative for SARS-CoV2 via NP swab.

199
200 Neurological complaints at baseline are described in table 1. The most complaint was confusion (27/39).
201 Less common complaints, occurring with or without confusion included: neck stiffness (14/39), headache
202 (12/39), new onset or increasing frequency of seizures (7/39), acute psychotic symptoms (10/39). On
203 neurological assessment, 5/39 had new onset hemiplegia and 1/39 had new onset bilateral lower limb
204 weakness. In the absence of other motor or sensory disturbance, 1/39 had new onset lower motor neuron
205 facial nerve (VII cranial nerve) weakness, and 1/39 had abducens (VI cranial nerve). Neurological
206 complaints at presentation in those testing positive for SARS-CoV2 on NP swab included: confusion (4/7)
207 of which 1/7 demonstrated acute psychotic symptoms, new onset seizures (1/7), headache and neck
208 stiffness (1/7), acute onset right sided weakness (1/7) and bilateral lower limb weakness (1/7). Of these 7
209 participants, 3 had no classical symptoms of COVID-19 (cough, shortness of breath, fever, anosmia or
210 dysgeusia). Between those with and without a positive NP swab for SARS-CoV2, there was no significant
211 difference in the neurological complaints at baseline. In 7 patients with a confirmed diagnosis of COVID-
212 19 (SARS-CoV2 positive PCR on NP swab); 2/7 were thought to have COVID-19 pneumonia with stroke
213 (see table 4), 1/7 presented with a clinical diagnosis of myelitis treated as possible viral or *M. tb* in
214 aetiology, with the remaining 4/7 patients, all of which presented with confusion, thought to be due to
215 delirium secondary to COVID-19 pneumonia. No further investigation was performed to formally assess
216 for encephalopathy.

217 Baseline blood and CSF analysis are described in table 2. This analysis was performed as part of routine
218 care, where there was a clinical indication and therefore not all tests were performed on every participant.
219 There was no difference in CSF markers to suggest an acute infective or inflammatory process in those
220 who tested positive for SARS-CoV2 via NP swab, versus those who did not, this includes: lymphocyte
221 count ($p=0.62$), polymorphonuclear cells ($p=0.39$) and protein ($p=0.59$). CSF glucose was significantly
222 higher in those with a diagnosis of COVID-19 (5.0 vs 3.0, $p=0.01$); however, of note HbA1C (%) was
223 significantly higher in patients with COVID-19 than in those without (13.0 vs 7.25, $p=0.02$), reflecting the

224 non-significant higher proportion of patients with pre-existing diabetes mellitus in those with a diagnosis of
225 COVID-19 compared to those without (2/7 vs 4/32, $p=0.29$).

226 Computerised Tomography (CT) scans of the brain were performed at baseline in 26/39 participants, of
227 which 2 were performed in patients with a confirmed diagnosis of COVID-19. 3/26 scans were performed
228 with contrast enhancement. Radiological findings at baseline are summarized in table 3. In the two scans
229 performed in patients with COVID-19, one demonstrated multi-focal subacute infarcts within the left
230 middle cerebral artery (MCA) and anterior deep borderzone territories. In the second, imaging
231 demonstrated multi-territory mature infarcts in in both cerebral hemispheres and in the cerebellum (figure
232 1). In both patients, CSF findings were unremarkable (see table 4), and a diagnosis of COVID-19
233 pneumonia with presumed diagnosis of stroke (clinical in the former, radiological in the latter) was made.

234

235 Multiplex PCR (targeting nucleocapsid (N), spike protein (S) and Orf1ab) runs revealed no evidence of
236 SARS-CoV2 in any of the 39 samples. Using the primer combinations for E gene readout and
237 subgenomic readout repeatedly gave no or weak ($C_t > 37$) signals that were interpreted as negative.
238 Therefore, none of the 39 samples demonstrated SARS-CoV2 via any of the PCR primer combinations
239 applied. Raw data is presented in table 1 of the supplementary material.

240

241 **Discussion**

242

243 We describe a cohort of patients presenting with clinical symptoms suggestive of possible neuroinfective
244 or neuroinflammatory aetiology, with and without symptoms and a confirmatory diagnosis of COVID-19
245 during the first peak of the pandemic in a resource poor setting in South Africa. Examination of the CSF
246 using PCR for multiple targets was negative in all cases therefore suggesting little evidence of direct
247 neurotropic invasion of SARS-CoV2 in CNS.

248

249 Published reports provide rationale for direct neurotropic invasion of SARS-CoV2 including cases of
250 meningitis and encephalitis where PCR for SARS-CoV2 was positive in CSF with and without classical
251 symptoms of COVID-19 [2] [[18]. At autopsy, SARS-CoV2 RNA has been detected in the brains of

252 patients who have died due to COVID-19 albeit at titers lower than in other affected organs [19, 20].
253 Evidence for direct neurotropic invasion is supported by findings from the 2002 SARS-CoV outbreaks
254 where studies demonstrated the presence of coronavirus particles in the brain [21-23], with subsequent
255 studies describing penetration of the CNS via the olfactory nerve [24]. In SARS-CoV2, a case of olfactory
256 gyrus intracerebral hemorrhage, an uncommon location for spontaneous hemorrhage, as well as the high
257 rates of anosmia, has highlighted whether SARS-CoV2 can invade neurological structures such as the
258 olfactory bulb via nasal mucosa [25]. Entry into the CNS via synaptic connections may also provide
259 rationale to consider a centrally-driven contribution to cardiorespiratory dysfunction in coronaviruses,
260 where acute onset respiratory failure leads to significant morbidity and mortality [36]. These observations
261 have, during the course of the COVID-19 pandemic, raised questions as to whether SARS-CoV2 should
262 be investigated as a causative organism, particularly in patients presenting with a meningitis or
263 encephalitis in a setting where SARS-CoV2 infection rates are high, both in those with and without a
264 confirmed diagnosis of COVID-19. In our cohort who were enrolled sequentially in a tertiary setting for
265 COVID-19 care, despite detailed examination of the CSF for presence of SARS-CoV2 using PCR primers
266 for genomic and subgenomic RNA, no patients were found to have evidence of direct neurotropic invasion
267 to the CNS. This finding is important in shaping the direction of clinical care in the management of
268 patients presenting with neurological symptoms in the COVID-19 era, particularly in resource limited
269 settings where the prioritisation of investigations is an important consideration in clinical care.

270
271 In our study, one patient had a clinical presentation consistent with myelitis alongside a diagnosis of
272 COVID-19, however in this case an explanation other than SARS-CoV2 infection was thought more likely
273 to account for their clinical presentation, and no evidence of direct neurotropic invasion of SARS-CoV2
274 was found. Acute myelitis [26] is one of many cases reported in the literature where the mechanism was
275 thought due to a post or para-infectious inflammatory response to SARS-CoV2. Other cases which may
276 suggest inflammatory sequelae occurring during or following SARS-CoV2 infection include: acute
277 necrotising hemorrhagic encephalopathy [27, 28], Guillain Barre Syndrome [10-12, 29] and Miller Fisher
278 Syndrome [30], and acute disseminated encephalomyelitis [31, 32], all of which occurred without
279 evidence of SARS-CoV2 in the CSF. Given that within our cohort direct neurotropic invasion of the CNS

280 was not found, these results might suggest that greater emphasis should now turn towards understanding
281 the role of inflammation at the time of or following SARS-CoV2 infection in a subset of patients.

282
283 Moreover, the proportional contribution of the now well-described coagulopathy leading to endothelial
284 dysfunction and eventual end organ damage is unknown [33]. This is particularly important to understand
285 in the context of stroke in patients with COVID-19; now frequently reported to occur where otherwise no
286 clear vascular risk factors exist [34, 35]. In our cohort, two patients presented with presumed stroke
287 alongside COVID-19 pneumonia. In both cases, vascular risk factors co-existed and may in part or
288 completely explain the vascular complications. Further research is required to understand the interplay of
289 the presumed coagulopathy both on pre-existing vascular risk factors such as hypertension and diabetes,
290 and other stroke risk factors such as HIV, particularly within the South African context.

291
292 There were several limitations to this study. Given the pragmatic nature of its design, only data on
293 investigations indicated as part of routine clinical care were available for analysis, resulting in an
294 incomplete laboratory and radiological data set. This includes cerebral imaging, which was not performed
295 in all participants, and in instances where it was, contrast was not given in the majority (23/26) of cases.
296 Factors related to coagulation, such as D-Dimer levels, would have provided interesting comparison of
297 patients presenting with complications such as stroke with and without confirmed COVID-19. In contrast,
298 laboratory procedures related to the discovery of SARS-CoV2 in CSF were thorough and robust, which
299 reassures that despite multiple runs, the negative findings are reliable.

300
301 Although small, this pragmatic observational cohort study contributes knowledge to our increasing
302 understanding of COVID-19 management. Through systematic analysis of CSF in patients presenting
303 with neurological symptoms in a context where incidence of SARS-CoV2 infection is high we have
304 demonstrated that although cases within the literature exist, direct neurotropic invasion of the CNS is
305 uncommon. This includes suspected cases of meningitis and encephalitis, syndromes most aligned to
306 direct neurotropic mechanism. This considered, neurological presentations in cases of COVID-19
307 continue to be reported, and lead to morbidity and mortality in patients affected. The results from our

308 study suggest that the further emphasis must now turn towards understanding the role of inflammation
309 and coagulopathy in the development of neurological syndromes. This includes studies to assess the
310 efficacy of proven anti-inflammatory drugs such as corticosteroids and tocilizumab, and therapeutics to
311 manage acute stroke in the treatment of patients who develop neurological symptoms due to SARS-CoV2
312 infection.

313

314

315

316 **References**

317

- 318 1. *Clinical findings in a group of patients infected with the 2019 novel coronavirus*
319 *(SARS-Cov-2) outside of Wuhan, China: retrospective case series.* BMJ, 2020. **368**: p.
320 m792.
- 321 2. Moriguchi, T., et al., *A first case of meningitis/encephalitis associated with SARS-*
322 *Coronavirus-2.* Int J Infect Dis, 2020. **94**: p. 55-58.
- 323 3. Khodamoradi, Z., et al., *COVID-19 meningitis without pulmonary involvement with*
324 *positive cerebrospinal fluid PCR.* Eur J Neurol, 2020. **27**(12): p. 2668-2669.
- 325 4. Espinosa, P.S., et al., *Neurological Complications of Coronavirus Disease (COVID-19):*
326 *Encephalopathy, MRI Brain and Cerebrospinal Fluid Findings: Case 2.* Cureus, 2020.
327 **12**(5): p. e7930.
- 328 5. Beyrouti, R., et al., *Characteristics of ischaemic stroke associated with COVID-19.* J
329 Neurol Neurosurg Psychiatry, 2020. **91**(8): p. 889-891.
- 330 6. Kang Zhao, J.H., Dan Dai, Yuwei Feng, Liming Liu, Shuke Nie, *Acute myelitis after*
331 *SARS-CoV-2 infection: a case report.* medRxiv 2020.03.16.20035105.
- 332 7. Sarma, D. and L.A. Bilello, *A Case Report of Acute Transverse Myelitis Following Novel*
333 *Coronavirus Infection.* Clin Pract Cases Emerg Med, 2020. **4**(3): p. 321-323.
- 334 8. Valiuddin, H., B. Skwirsk, and P. Paz-Arabo, *Acute transverse myelitis associated with*
335 *SARS-CoV-2: A Case-Report.* Brain Behav Immun Health, 2020. **5**: p. 100091.
- 336 9. de Miranda Henriques-Souza, A.M., et al., *Acute disseminated encephalomyelitis in a*
337 *COVID-19 pediatric patient.* Neuroradiology, 2021. **63**(1): p. 141-145.
- 338 10. Sedaghat, Z. and N. Karimi, *Guillain Barre syndrome associated with COVID-19*
339 *infection: A case report.* J Clin Neurosci, 2020. **76**: p. 233-235.
- 340 11. El Otmani, H., et al., *Covid-19 and Guillain-Barre syndrome: More than a coincidence!*
341 *Rev Neurol (Paris), 2020. 176(6): p. 518-519.*
- 342 12. Alberti, P., et al., *Guillain-Barre syndrome related to COVID-19 infection.* Neurol
343 Neuroimmunol Neuroinflamm, 2020. **7**(4).
- 344 13. Toscano, G., et al., *Guillain-Barre Syndrome Associated with SARS-CoV-2.* N Engl J
345 Med, 2020. **382**(26): p. 2574-2576.

- 346 14. Sykes, W., et al., *Prevalence of anti-SARS-CoV-2 antibodies among blood donors in*
347 *Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South*
348 *Africa in January 2021*. Res Sq [Preprint]. 2021 Feb 12:rs.3.rs-233375.
- 349 15. <https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa?bc=254>.
- 350 16. Wolfel, R., et al., *Virological assessment of hospitalized patients with COVID-2019*.
351 *Nature*, 2020. **581**(7809): p. 465-469.
- 352 17. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time*
353 *RT-PCR*. Euro Surveill, 2020. **25**(3): pii=2000045.
- 354 18. Khodamoradi, Z., et al., *COVID-19 meningitis without pulmonary involvement with*
355 *positive cerebrospinal fluid PCR*. Eur J Neurol. 2020 Dec;**27**(12):2668-266919.
- 356 19. Wichmann, D., et al., *Autopsy Findings and Venous Thromboembolism in Patients*
357 *With COVID-19: A Prospective Cohort Study*. Ann Intern Med, 2020. **173**(4): p. 268-
358 277.
- 359 20. Puelles, V.G., et al., *Multiorgan and Renal Tropism of SARS-CoV-2*. N Engl J Med,
360 2020. **383**(6): p. 590-592.
- 361 21. Ding, Y., et al., *Organ distribution of severe acute respiratory syndrome (SARS)*
362 *associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis*
363 *and virus transmission pathways*. J Pathol, 2004. **203**(2): p. 622-30.
- 364 22. Gu, J., et al., *Multiple organ infection and the pathogenesis of SARS*. J Exp Med, 2005.
365 **202**(3): p. 415-24.
- 366 23. Xu, J., et al., *Detection of severe acute respiratory syndrome coronavirus in the brain:*
367 *potential role of the chemokine mig in pathogenesis*. Clin Infect Dis, 2005. **41**(8): p.
368 1089-96.
- 369 24. Netland, J., et al., *Severe acute respiratory syndrome coronavirus infection causes*
370 *neuronal death in the absence of encephalitis in mice transgenic for human ACE2*. J
371 Virol, 2008. **82**(15): p. 7264-75.
- 372 25. Thu, S.S., N. Matin, and S.R. Levine, *Olfactory gyrus intracerebral hemorrhage in a*
373 *patient with COVID-19 infection*. J Clin Neurosci, 2020. **79**: p. 275-276.
- 374 26. Kang Zhao, J.H., Dan Dai, Yuwei Feng, Liming Liu, Shuke Nie, *Acute myelitis after*
375 *SARS-CoV-2 infection: a case report*. medRxiv 2020.03.16.20035105
- 376 27. Rossi, A., *Imaging of acute disseminated encephalomyelitis*. Neuroimaging Clin N Am,
377 2008. **18**(1): p. 149-61

- 378 28. Poyiadji, N., et al., *COVID-19-associated Acute Hemorrhagic Necrotizing*
379 *Encephalopathy: CT and MRI Features*. Radiology, 2020; 296(2): p. 201187.
- 380 29. Toscano, G., et al., *Guillain-Barre Syndrome Associated with SARS-CoV-2*. N Engl J
381 Med. 2020;382(26):2574-2576.
- 382 30. Gutierrez-Ortiz, C., et al., *Miller Fisher Syndrome and polyneuritis cranialis in COVID-*
383 *19*. Neurology Aug 2020, 95 (5) e601-e605
- 384 31. Parsons, T., et al., *COVID-19-associated acute disseminated encephalomyelitis*
385 *(ADEM)*. J Neurol. 2020 Oct;267(10): p. 2799-2802
- 386 32. Novi, G., et al., *Acute disseminated encephalomyelitis after SARS-CoV-2 infection*.
387 Neurol Neuroimmunol Neuroinflamm, 2020. **7**(5): e797
- 388 33. Hess, D.C., W. Eldahshan, and E. Rutkowski, *COVID-19-Related Stroke*. Transl Stroke
389 Res, 2020. **11**(3): p. 322-325.
- 390 34. Goldberg, M.F., et al., *Cerebrovascular Disease in COVID-19*. AJNR Am J Neuroradiol.
391 2020 Jul;41(7):1170-1172.
- 392 35. Avula, A., et al., *COVID-19 presenting as stroke*. Brain Behav Immun, 2021; 87: 115-
393 119
- 394

5 **Table 1 Baseline characteristics**

	All	SARS-CoV2 -ve on NP swab or unknown SARS-CoV2 status	SARS-CoV2 +ve on NP swab
n	39	32	7
Gender			
Male	15	11	4
Female	24	21	3
Age (years)			
Median (range)	44 (27-84)	42 (27-79)	47 (42-84)
HIV seropositivity			
HIV co-infected	22	19	3
On ART	11	8	3
ART naïve/defaulted	11	11	0
HIV uninfected	13	11	2
Not known	4	2	2
HIV-1 VL (copies/ml) (n=13, median ; IQR)	75831; 28,0141	253,344; 258,249	205; 206
CD4 Cell count (cells/mm3) (nr 332-1642) (n=16, median; IQR)	35.5; 186	32; 99	260; 69
Comorbidities			
Cardiovascular Disease	2	2	0
Hypertension	13	9	4
Diabetes Mellitus	4	4	2
Obesity	15	11	4
Underlying Respiratory Disease	5	5	0
Chronic Kidney Disease	1	0	1
Baseline Symptoms			
Cough	17	12	5
Fever	7	3	4
Dyspnoea	11	7	4
Lethargy	10	9	1
Nausea	3	3	0
Diarrhoea	11	10	1
Headache	12	11	1
Neck Stiffness	14	13	1
Seizures	7	6	1
Agitation/psychosis	10	9	1
Confusion	27	23	4
Anosmia/Dysgeusia	1	0	1
Days symptomatic median (IQR)	7 (13)	8 (13)	7 (5)
Baseline Neurological Examination			
Hemiplegia	5	4	1
Paraplegia	1	0	1
Cerebellar ataxia	0	0	0
Tremor	0	0	0
Seizures	1	1	0
Cranial Nerve Abnormality	4	4	0
Glasgow Coma Score (Median)	14	14	14

6

7

8 **Table 2: Blood and CSF analysis.**

	Value expressed as	Performed in (n)	Normal range	All participants	SARS-CoV2 -ve on NP swab or unknown SARS-CoV2 status	SARS-CoV2 +ve on NP swab	p values
Blood							
Hemoglobin (g/dL)	Median; IQR	39	12-15	11.5 ; 4	11.1 ; 2	12.3 ; 2	
Platelets (cells x10 ⁹ /L)		37	186-454	281 ; 140	281 ; 116	271 ; 168	
White cells (cells x10 ⁹ /L)		39	3.9 – 12.6	8.4 ; 9	8.3 ; 7	8.4 ; 9	
Neutrophils (cells x10 ⁹ /L)		15	1.6 – 8.3	6.0 ; 0	7.8 ; 7	4.4 ; 1	
Lymphocytes (cells x10 ⁹ /L)		15	1.4 – 4.5	1.12 ; 12	(In 13/15), 1.12 ; 1	(in 2/15), 8.56 ; 8	
Eosinophils (cells x10 ⁹ /L)		15	0.0 – 0.4	0.02 ; 0	0.02 ; 0	0.01 ; 0	
C-Reactive Protein (mg/L)			<10	68 ; n/a	47 ; n/a	110 ; n/a	<i>p=0.36</i>
Erythrocyte Sedimentation Rate (mm/hr)		5	0-10	96 ; n/a	96 ; 67	n/a ; n/a	
Ferritin (µg/L)		3	11-307	83 ; n/a	83 ; 492	n/a ; n/a	
D Dimer (ng/mL)		14	0 – 0.25	1.25 ; 2	1.32 ; 1	0.66 ; 2	
ALT (IU/l)		32	19-25	29.5 ; 15	32 ; 27	19 ; 16	
Total Bili (µmol/L)		32	5-21	12 ; 8	11 ; 12	15 ; 6	
Na+ (mmol/L)		39	136-145	136 ; 9	135 ; 10	137 ; 6	
K+ (mmol/L)		39	3.5-5.1	3.9 ; 0	4.0 ; 1	3.8 ; 0	
Creatinine (µmol/L)		39	49-90	79.0 ; 24	82.5 ; 64	72.0 ; 18	
Total Protein (g/L)	24	6-78	75.0 ; 14	75.0 ; 13	76.5 ; 10		
HbA1C (%)	7	4-5.6	7.9 ; 6	7.25 ; 2	13.0 ; 0	<i>p=0.02</i>	
Cerebrospinal Fluid							
Polymorphonuclear cells (cells/µL)	Median; IQR; range	38	<3	0 ; 6; 0-118	0 ; 1; 0-118	0 ; 0; 0-0	<i>p=0.39</i>
Lymphocytes (cells/µL)		38	<3	0 ; 6; 0-2073	0 ; 9; 0-2073	2 ; 4; 0-12	<i>p=0.62</i>
Erythrocytes (cells/µL)		38	<3	5 ; 48; 3-349	3 ; 17; 0-349	62 ; 148; 0-311	<i>P=0.28</i>
Protein (g/L)		39	0.15-0.45	0.39 ; 1; 0.13-4.82	0 ; 1; 0.13 – 4.82	0 ; 0; 0.17 – 2.19	<i>p=0.56</i>
Glucose (mmol/L)		39		3 ; 3; 0.1-10.2	3 ; 2; 0.1-7.0	5 ; 5; 2.8 – 10.2	<i>p=0.01</i>
Bacterial Culture	n, (% positive)	39		5/39 (12.8)	4/32 (12.5)	1/7 (14.2)	<i>p=0.90</i>
CLAT	n, (% positive)	32		5/32 (15.6)	5/29 (17.2)	0/3 (0)	
GXPU	n, (% positive)	22		1/22 (45.5)	1/18 (5.5)	0/4 (0)	
PCR for SARS-CoV2 in CSF							
Positive CT value for E		39		0/39	0/32	0/7	
Positive CT value for sgRNA		39		0/39	0/32	0/7	

Values expressed as Median; Interquartile Range (IQR); Range, or n (% positive). Abbreviations: Na+: sodium; K+: potassium; CLAT: cryptococcal latex agglutination titre; GXPU: GeneXpert Ultra; CT (cycle threshold); sgRNA: subgenomic RN.

9
0
1
2
3

4 **Table 3: Radiological analysis**

Radiological Finding	All participants	SARS-CoV2 -ve on NP swab or unknown SARS-CoV2 status	SARS-CoV2 +ve on NP swab
Leptomeningeal Enhancement	1/26	1/24	0/2
Hydrocephalus	3/26	3/26	0/2
of which communicating	3/26	3/26	n/a
Radiological evidence of infarcts	14/26	13/26	1/2
of which new	3/14	3/13	0/1
single	10/14	9/13	1/1
multiple	4/14	4/13	0/1
Territory			
Middle cerebral artery territory	9/14	8/13	1/1
Anterior cerebral artery territory	0/14	0/13	0/1
Posterior cerebral artery territory	0/14	0/13	0/1
Ring enhancing lesions	0/26	0/24	0/2
Effacement	1/26	1/24	0/2
Of which local sulcal	1/26	1/24	0/2
Of which hemispheric sulcal	1/26	1/24	0/2
Of which global sulcal	0/26	0/24	0/2
Of which basal cistern	0/26	0/24	0/2


5
6
7
8
9
0
1
2
3
4
5
6

7 **Table 4: Detailed clinical presentations, laboratory findings in patients presenting with COVID-19 and neurological symptoms**

Age range, Gender	HIV status, VL, CD4	Co-morbidities	Baseline symptoms and examination findings	Significant blood and CSF findings (Units as described in table 2)*	Radiological findings	Final diagnosis
50-50 M	Neg	Nil	2 day history of cough, fever, seizures (unclear if new onset) and confusion. GCS 14 on assessment	Blood: Hb 10.7, WCC 23 (eosinophils 291), CRP 110, Na 132. CSF: Lymphocytes 2, erythrocytes 13, protein 0.17, glucose 4.7, normal gram stain, negative bacterial culture	Not done	COVID pneumonia with confusion +/- new onset/worsening seizure frequency
40-50 F	UNK	Hypertension, DM, Obesity	2 day history of shortness of breath, anosmia, worsening confusion and agitation. GCS 7 on assessment with no focal neurological abnormalities	Blood: WCC 15, CRP 77, Na 147 CSF: Lymphocytes 1, Erythrocytes 62, protein 0.19, glucose 7.8, occasional lymphocytes on gram stain, negative bacterial culture	Not done	COVID pneumonia, with DKA/HHS
40-50 M	Pos, VL undetectable, CD4 329, unknown treatment status	Obesity	7 day history of cough, fever, sore throat, headache and neck stiffness. GCS 15 and unremarkable neurological examination.	Blood: WCC 5, CRP 74 CSF: Lymphocytes 2, erythrocytes 76, protein 0.42, glucose 5.5, negative gram stain and bacterial culture, GXPU trace on first LP, negative on second. TB culture negative.	Not done	COVID pneumonia, no cause for neurological symptoms identified
40-50 M	Neg	Hypertension	7 day history of cough, shortness of breath, sore throat and fever, new onset right sided weakness. Examination revealed reduced power (MRC 3/5 throughout) in right upper and lower limbs. GCS 15.	Blood: WCC 14, CRP 196. CSF: WCC 0, CSF protein 0.3, CSF glucose 3.0 (no blood glucose comparator), negative gram stain, no growth on bacterial culture, negative GXPU and CLAT.	Subacute left MCA territory infarct	COVID-19 pneumonia and stroke
60-70 F	Pos, unknown VL, CD4 191, on ART	Hypertension, DM, Obesity	7 day history of cough, shortness of breath and increasing confusion. GCS 14.	Blood: WCC 7, CRP 453, Na 130, D Dimer 4.94 CSF lymphocytes 4, erythrocytes 311, CSF protein 0.3, CSF glucose 10.2 (no blood glucose comparator), occasional lymphocytes seen on gram stain, negative bacterial culture, negative GXPU and CLAT.	Multi-territory mature infarcts in both cerebral hemispheres and in the cerebellum.	COVID-19 pneumonia and radiological diagnosis of multifocal infarcts
40-50 F	Pos, VL 411, CD4 unknown, on ART	Obesity	20 day history of GI symptoms with increasing weakness in both lower limbs. Pyramidal distribution weakness, hyperreflexia, T8 sensory level	CSF: Lymphocytes 12, erythrocytes 161, protein 2.19, glucose 2.8, Viral PCR positive for Epstein-Barr virus, HIV-1 viral load 838368 copies/mL	No brain imaging done MRI spine reported as showing expanded poorly enhancing STIR/T2W hyperintense T7-T12 spinal cord associated with subtle enhancement of the adjacent leptomeninges. Arachnoiditis. Impression of cauda equina syndrome.	Viral myelitis with HIV CSF escape
80-90 F	Unknown,	Nil	7 day history of cough, fever, shortness of breath, lethargy, increasing confusion	Blood: Hb 10.0 CSF: WCC 0. protein 0.3, glucose 4.5, GS occasional lymphocytes, bacterial culture negative	No brain imaging done	COVID-19 pneumonia with new onset confusion

* See table 2 for units of blood and CSF markers. Abbreviations: STIR: Short-TI Inversion Recovery; T2W: T2 weighted sequences; DKA: Diabetic Ketoacidosis; HHS: Hyperosmolar Hyperglycaemic State; DM: Diabetes Mellitus; ART: Antiretroviral Therapy; UNK: Unknown; Neg: Negative; Pos: Positive; VL: Viral Load;

1 **Figure 1:** Axial unenhanced CT head imaging in two patients where a diagnosis of COVID-19 was confirmed (PCR for SARS-CoV2 positive on NP swab).
2 Top row demonstrates poorly-defined multifocal cortical and subcortical hypodensities in keeping with subacute left middle cerebral artery territory (A,C) and
3 anterior deep borderzone territory (B) infarcts. Bottom row demonstrates multi-territory mature infarcts in the right middle cerebral artery territory (D) and left
4 posterior inferior cerebellar artery territory (E).
5



6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2

3 **Supplementary Material**

4 **Table 1: Results of CSF PCR analysis for detection of SARS-CoV2 (Supplementary data)**

Sample CODE	Primers	CT (run 22.1.21)	Freshly isolated RNA from 300ul CSF (run 1)	Freshly isolated RNA from 1ml CSF (run 2)
NTC	E/sgRNA/RP	U/U/U		
negative RNA	E/sgRNA/RP	U/U/19.64	Not run	Not run
positive RNA	E/sgRNA/RP	29.588/35.725/23.228		
A	E/sgRNA/RP	U/U/27.838	U/U/28.543	Not run
B	E/sgRNA/RP	U/U/32.167	U/U/31.723	Not run
C	E/sgRNA/RP	U/U/30.423	U/U/30.291	Not run
D	E/sgRNA/RP	U/U/33.769	U/U/34.833	Not run
E	E/sgRNA/RP	U/U/29.596	U/U/28.904	Not run
F	E/sgRNA/RP	U/U/29.508	U/U/29.433	Not run
G	E/sgRNA/RP	U/U/30.766	U/U/31.742	Not run
H	E/sgRNA/RP	U/U/28.1	U/U/27.882	Not run
J	E/sgRNA/RP	U/U/28.301	U/U/26.715	Not run
K	E/sgRNA/RP	U/U/30.967	U/U/31.610	Not run
L	E/sgRNA/RP	U/U/32.565	U/U/29.195	Not run
M	E/sgRNA/RP	U/U/29.434	U/U/31.586	Not run
N	E/sgRNA/RP	U/U/30.329	U/U/30.767	Not run
P	E/sgRNA/RP	U/U/32.947	U/U/32.885	Not run
Q	E/sgRNA/RP	U/U/32.693	U/U/33.181	Not run
R	E/sgRNA/RP	U/U/31.684	U/U/31.898	Not run
S	E/sgRNA/RP	U/U/31.920	U/U/32.882	Not run
T	E/sgRNA/RP	U/U/30.518	U/U/30.682	Not run
U	E/sgRNA/RP	U/U/21.694	U/U/21.572	Not run
V	E/sgRNA/RP	U/U/31.449	U/U/32.053	Not run
W	E/sgRNA/RP	U/U.27.471	U/U/26.683	Not run
X	E/sgRNA/RP	U/U/26.666	U/U/27.990	Not run
Y	E/sgRNA/RP	U/U/28.835	U/U/28.412	Not run
Z	E/sgRNA/RP	U/U/27.502	Not run	Not run
A2	E/sgRNA/RP	U/U/28.626	Not run	Not run
B2	E/sgRNA/RP	U/U/29.912	Not run	Not run
C2	E/sgRNA/RP	U/U/31.769	Not run	Not run
D2	E/sgRNA/RP	U/U/23.736	Not run	Not run
E2	E/sgRNA/RP	37.867/39.461/30.956	Not run	U/U/29.642
F2	E/sgRNA/RP	U/U/24.674	Not run	U/U/30.549
G2	E/sgRNA/RP	U/38.837/31.717	Not run	U/U/30.549
H2	E/sgRNA/RP	40.430/U/27.301	Not run	U/U/24.015
J2	E/sgRNA/RP	U/U/26.379	Not run	Not run
K2	E/sgRNA/RP	U/U/29.545	Not run	Not run
L2	E/sgRNA/RP	U/38.438/23.510	Not run	U/U/21.109
M2	E/sgRNA/RP	U/U/29.039	Not run	Not run
N2	E/sgRNA/RP	U/U/19.058	Not run	Not run
P2	E/sgRNA/RP	U/38.087/27.014	Not run	U/U/29.229

5 Abbreviations: CT (cycle threshold), CSF (cerebrospinal fluid), NTC (no template control), RP (RNaseP), U (Undetermined)

6